We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2.32B
1-Year Est. Return 536.01%
This Fund
S&P 500
This Quarter Est. Return
+62.61%
1 Year Est. Return
+536.01%
3 Year Est. Return
+1,584.92%
5 Year Est. Return
+2,855.24%
10 Year Est. Return
–
AUM
$1.17B
AUM Growth
+$385M
Cap. Flow
+$29M
Cap. Flow %
2.49%
Top 10 Hldgs %
67.93%
Holding
74
New
28
Increased
5
Reduced
17
Closed
15

Top Buys

Rank Stock Value
1
OLMA icon
Olema Pharmaceuticals
OLMA
+$176M
2
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
+$22.9M
3
CCCC icon
C4 Therapeutics
CCCC
+$13.9M
4
ABCL icon
AbCellera Biologics
ABCL
+$13.7M
5
COGT icon
Cogent Biosciences
COGT
+$13.7M

Top Sells

Rank Stock Value
1
KROS icon
Keros Therapeutics
KROS
+$72.5M
2
GBT
Global Blood Therapeutics, Inc.
GBT
+$46.9M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$38.6M
4
TGTX icon
TG Therapeutics
TGTX
+$30.4M
5
CLDX icon
Celldex Therapeutics
CLDX
+$17.8M

Sector Composition

Rank Sector Weight
1 Healthcare 97.34%
2 Miscellaneous 2.66%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALXO icon
1
ALX Oncology
ALXO
$242M
$272M 23.33%
3,156,981
+20,000
+0.6% +$1.2M
OLMA icon
2
Olema Pharmaceuticals
OLMA
$853M
$180M 15.43%
+3,743,875
New +$176M
NKTX icon
3
Nkarta
NKTX
$197M
$103M 8.86%
1,682,178
-365,000
-18% -$15.2M
FMTX
4
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$48.9M 4.19%
1,400,000
+226,812
+19% +$9.87M
TGTX icon
5
TG Therapeutics
TGTX
$8.63B
$44.2M 3.79%
850,000
-900,000
-51% -$30.4M
DYN icon
6
Dyne Therapeutics
DYN
$3.3B
$33.7M 2.89%
1,604,392
– –
LONA
7
LeonaBio Inc
LONA
$65M
$32.5M 2.78%
94,787
-7,294
-7% -$1.72M
KROS icon
8
Keros Therapeutics
KROS
$218M
$31.7M 2.72%
450,000
-1,150,000
-72% -$72.5M
RPTX
9
DELISTED
Repare Therapeutics
RPTX
$23.2M 1.99%
676,894
-300,000
-31% -$8.96M
KNTE
10
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$22.7M 1.94%
+569,602
New +$22.9M
COGT icon
11
Cogent Biosciences
COGT
$5.74B
$21.6M 1.85%
1,920,500
+1,245,500
+185% +$13.7M
BTAI
12
DELISTED
BioXcel Therapeutics
BTAI
$19.9M 1.7%
26,875
-7,500
-22% -$5.84M
APLS
13
DELISTED
Apellis Pharmaceuticals
APLS
$17.2M 1.47%
+300,000
New +$12.7M
BHVN
14
CALL
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$17.1M 1.47%
+200,000
New +$16.9M
RNAM
15
DELISTED
Avidity Biosciences
RNAM
$17.1M 1.47%
671,454
-50,000
-7% -$1.46M
ALGS icon
16
Aligos Therapeutics
ALGS
$32.5M
$16.8M 1.44%
+24,262
New +$11.8M
CCCC icon
17
C4 Therapeutics
CCCC
$421M
$15.8M 1.36%
+477,928
New +$13.9M
LRMR icon
18
Larimar Therapeutics
LRMR
$405M
$15.3M 1.31%
715,000
+385,000
+117% +$7.72M
CMPS
19
Compass Pathways
CMPS
$2.05B
$14.3M 1.23%
300,000
-200,000
-40% -$8.53M
SPRY icon
20
ARS Pharmaceuticals
SPRY
$411M
$13.9M 1.19%
+300,000
New +$10M
IGMS
21
DELISTED
IGM Biosciences
IGMS
$13.2M 1.14%
+150,000
New +$10.5M
KRTX
22
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$12.2M 1.05%
+120,000
New +$11.1M
ABCL icon
23
AbCellera Biologics
ABCL
$4.17B
$12.1M 1.03%
+300,000
New +$13.7M
MRTX
24
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$11M 0.94%
+50,000
New +$10.8M
CALT
25
DELISTED
Calliditas Therapeutics AB American Depositary Shares
CALT
$10.1M 0.86%
300,000
-250,000
-45% -$7.61M
1
2 3

Similar funds

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
CWM
Cornerstone Wealth Management St. Peters, Missouri $2.33B AUM 25.21% 1-Year Est. Return
PA
Procyon Advisors Shelton, Connecticut $2.32B AUM 26.81% 1-Year Est. Return
NP
NS Partners London, United Kingdom $2.33B AUM 35.18% 1-Year Est. Return
AI
Accredited Investors Edina, Minnesota $2.31B AUM 33.7% 1-Year Est. Return
GGH
GCM Grosvenor Holdings Chicago, Illinois $2.31B AUM 18.36% 1-Year Est. Return
HHGA
Halbert Hargrove Global Advisors Long Beach, California $2.31B AUM 21.64% 1-Year Est. Return
TWA
TCI Wealth Advisors Tucson, Arizona $2.31B AUM 26.52% 1-Year Est. Return

Logos Global Management's Q4 2020 Portfolio in Review

As of Q4 2020, Logos Global Management held 74 positions worth $1.17B, up 49% from $781M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Logos Global Management's Q4 2020 filing shows 28 new, 5 increased, 17 reduced and 15 closed positions. Its largest new stake was Olema Pharmaceuticals: 3,743,875 shares worth $180M. The largest sale was Keros Therapeutics, an estimated $72.5M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 97% a quarter earlier, followed by Miscellaneous.

  • Logos Global Management's largest Q4 2020 buy was Olema Pharmaceuticals: 3,743,875 shares worth $180M.
  • Logos Global Management added most to Cogent Biosciences in Q4 2020, an estimated $13.7M increase.
  • Logos Global Management's biggest Q4 2020 reduction was Keros Therapeutics, cutting an estimated $72.5M.
  • Logos Global Management fully exited Global Blood Therapeutics, Inc. in Q4 2020, selling an estimated $46.9M.
  • Logos Global Management's ten largest holdings make up 68% of its $1.17B portfolio in Q4 2020.
  • Logos Global Management opened 28 new positions and closed 15 in Q4 2020.
  • Logos Global Management's portfolio value rose 49% quarter-over-quarter to $1.17B.

Based on Logos Global Management's 13F filing for Q4 2020, filed 16 Feb 2021.